Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

European Heart Journal

Volumn 31, Issue 11, 2010, Pages 1311-1318

  Lip, Gregory Y H ^a   Huber, Kurt ^b   Andreotti, Felicita ^c   Arnesen, Harald ^d   Airaksinen, Juhani K ^e   Cuisset, Thomas ^f   Kirchhof, Paulus ^g   Marín, Francisco ^h  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WILHELMINEN HOSPITAL   (Austria)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f TIMONE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Acute coronary syndrome; Antithrombotic therapy; Atrial fibrillation; Percutaneous coronary intervention; Stenting; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSENSUS; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DRUG ELUTING STENT; ELECTIVE SURGERY; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STANDARDIZATION; STENT THROMBOSIS; STROKE; THROMBOEMBOLISM; VASCULAR ACCESS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ATRIAL FIBRILLATION; EUROPE; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HEMORRHAGE; HUMANS; RISK FACTORS; STENTS; STROKE; THROMBOEMBOLISM;

EID: 77953189870     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq117     Document Type: Review

References (85)

1. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007;6: 981-993.
2. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423-434.
3. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-2434.
4. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006-1023. (Pubitemid 351773289)
5. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clo-pidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.
6. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-2037.
7. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005;104:101-106.
8. Bassand J, Hamm C, Ardissino D, Boersma E, Budaj A, Fernández- Avilés F, Fox K, Hasdai D, Ohman E, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1598-1660.
9. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
10. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030
11. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physician; 2006.
12. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-647.3395.
13. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiogra-phy, Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
14. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 (Suppl. 6):776S-814S.
15. Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Maŕin F, European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary inter-vention/stenting: a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010;103:13-28.
16. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, Sirbu V, Bass TA, Della Rovere F, Gavazzi A, Angiolillo DJ. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618-1623.
17. Rubboli A, Colletta M, Valencia J, Capecchi A, Franco N, Zanolla L, La Vecchia L, Piovaccari G, DI Pasquale G for the WARfarin, Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009;22:390-397.
18. Rubboli A, Halperin J, Airaksinen K, Buerke M, Eeckhout E, Freedman S, Gershlick A, Schlitt A, Tse H, Verheugt F, Lip G. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40:428-436.
19. Wang T, Robinson L, Ou F, Roe M, Ohman E, Gibler W, Smith SJ, Peterson E, Becker R. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008;155:361-368.
20. Ruiz-Nodar J, Maŕin F, Hurtado J, Valencia J, Pinar E, Pineda J, Gimeno J, Sogorb F, Valdés M, Lip G. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51:818-825.
21. Karjalainen P, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M, Airaksinen T, Niemelä M, Vahlberg T, Airaksinen K. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-732.
22. Stenestrand U, Lindbäck J, Wallentin L RIKS-HIA Registry. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 2005;112:3225-3231.
23. Larson B, Zumberg M, Kitchens C. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005;127:922-927.
24. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J, American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 (Suppl. 6):299S-339S.
25. MacDonald L, Meyers S, Bennett C, Fintel D, Grosshans N, Syegco R, Davidson C. Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization. J Invasive Cardiol 2003;15:60-62.
26. Annala A, Karjalainen P, Porela P, Nyman K, Ylitalo A, Airaksinen K. Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment. Am J Cardiol 2008;102:386-390.
27. Karjalainen P, Vikman S, Niemelä M, Porela P, Ylitalo A, Vaittinen M, Puurunen M, Airaksinen T, Nyman K, Vahlberg T, Airaksinen K. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008;29:1001-1010.
28. Wazni O, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, Martin D, Kanj M, Arruda M, Cummings J, Schweikert R, Saliba W, Natale A. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007;116:2531-2534.
29. Jessup D, Coletti A, Muhlestein J, Barry W, Shean F, Whisenant B. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy. Catheter Cardiovasc Interv 2003;60:180-184.
30. Helft G, Dambrin G, Zaman A, Le Feuvre C, Barthélémy O, Beygui F, Favereau X, Metzger JP. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv 2009;73:44-47.
31. ten Berg J, Hutten B, Kelder J, Verheugt F, Plokker H. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 2001;103: 2042-2047.
32. El-Jack S, Ruygrok P, Webster M, Stewart J, Bass N, Armstrong G, Ormiston J, Pornratanarangsi S. Effectiveness of manual pressure hemostasis following trans-femoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol 2006;97:485-488.
33. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300-313.
34. Boersma E, Harrington R, Moliterno D, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong P, Wallentin L, Wilcox R, Simes J, Califf R, Topol E, Simoons M. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
35. Manzano-Fernández S, Pastor F, Maŕin F, Cambronero F, Caro C, Pascual-Figal D, Garrido I, Pinar E, Valdés M, Lip G. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008;134:559-567.
36. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A Intracoronary Stenting, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
37. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A Intracoronary Stenting, Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-1538.
38. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358: 2218-2230.
39. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW Acute Catheterization, Urgent Intervention Triage strategy (ACUITY) Trial Investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-919.
40. Agostoni P, Biondi-Zoccai G, de Benedictis M, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004;44: 349-356.
41. Chase A, Fretz E, Warburton W, Klinke W, Carere R, Pi D, Berry B, Hilton J. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008;94:1019-1025.
42. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 2009;157:132-140.
43. Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004;291:350-357. (Pubitemid 38101608)
44. Bertrand M, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden E. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597-1603.
45. Urban P, Macaya C, Rupprecht H, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-2132.
46. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339: 1665-1671.
47. Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009;119:687-698.
48. Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G, Steg P, Morel M, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff M, Serruys P. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
49. Nguyen M, Lim Y, Walton A, Lefkovits J, Agnelli G, Goodman S, Budaj A, Gulba D, Allegrone J, Brieger D. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28:1717-1722.
50. Ruiz-Nodar JM, Marin F, Sanchez-Paya J, Hurtado JA, Valencia J, Manzano-Fernandez S, Roldan V, Perez-Andreu V, Sogorb F, Valdes M, Lip G. Efficay and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009;30:932-939.
51. Karjalainen P, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J, Tuomainen P, Nyman K, Airaksinen K. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention 2008;4:234-241.
52. Bartorelli A, Tamburino C, Trabattoni D, Galassi A, Serdoz R, Sheiban I, Piovaccari G, Zimarino M, Benassi A, Di Mario C, Sangiorgio P, Chierchia S, Reimers B. Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent. Am J Cardiol 2007;99:1062-1066.
53. Co M, Tay E, Lee C, Poh K, Low A, Lim J, Lim I, Lim Y, Tan H. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate-to long-term clinical follow-up. Am Heart J 2008;155:128-132.
54. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-Eluting Coronary Stent with the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients with Stenosis in Native Coronary Arteries. The NOBORI 1 Trial\Phase 2. Circulation: Cardiovasc Interv 2009;2:188-195.
55. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ACTIVE Investigators. N Engl J Med 2009;360:2066-2078.
56. Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost 2008;100:955-957.
57. Palareti G, Cosmi B. Bleeding with anticoagulation therapy\who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-278.
58. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)
59. Moscucci M, Fox K, Cannon C, Klein W, López-Sendón J, Montalescot G, White K, Goldberg R. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24: 1815-1823.
60. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009;119:1873-1882.
61. Circulation. 2009 119(14): 1846-1849
62. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock S, Lincoff A, Stone G. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007;28:1936-1945.
63. Sarafoff N, Ndrepepa G, Mehilli J, Dörrler K, Schulz S, Iijima R, Byrne R, Schömig A, Kastrati A. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagu-lation. J Intern Med 2008;264:472-480.
64. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-1517.
65. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4:2508-2509.
66. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944.
67. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-484.
68. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pan-toprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148 e141-145.
69. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman J, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopido-grel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-997.
70. Bhatt DL. COGENT: a Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. Presented at TCT 2009 San Francisco, 2009, http://www.tctmd.com/show.aspx?id=86168.
71. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009;11:860-885.
72. Torosian M, Michelson EL, Morganroth J, MacVaugh H 3rd. Aspirin-and coumadin-related bleeding after coronary-artery bypass graft surgery. Ann Intern Med 1978;89:325-328.
73. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
74. Kim JH, Newby LK, Clare RM, Shaw LK, Lodge AJ, Smith PK, Jolicoeur EM, Rao SV, Becker RC, Mark DB, Granger CB. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008;156:886-892.
75. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006;18:162-164.
76. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147: 463-467.
77. Maegdefessel L, Schlitt A, Faerber J, Bond SP, Messow CM, Buerke M, Raaz U, Werdan K, Muenzel T, Weiss C. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) 2008;103:628-632.
78. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-1827.
79. Rogacka R, Chieffo A, Michev I, Airoldi F, Latib A, Cosgrave J, Montorfano M, Carlino M, Sangiorgi GM, Castelli A, Godino C, Aranzulla TC, Romagnoli E, Colombo A. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral antiocoagulation. J Am Coll Cardiol Interv 2008;1:56-61.
80. Porter A, Konstantino Y, Iakobishvili Z, Shachar L, Battler A, Hasdai D. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006;68: 56-61.
81. Manzano-Fernandez S, Marin F, Pastor-Perez FJ, Caro C, Cambronero F, Lacunza J, Pinar E, Pascual-Figal DA, Valdes M, Lip GY. Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting. Chest 2009; 135:983-990.
82. DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, Ruggiero N, Singhal S, Greenspon A. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007;27: 691-696.
83. Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, Moses JW, Stone GW, Leon MB, Pocock SJ, Dangas G. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 2004;44:1200-1209.
84. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM TRITON-TIMI 38 Investigators. Prasu-grel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
85. Khoo CW, Tay KH, Shantsila E, Lip GY. Novel oral anticoagulants. Int J Clin Pract 2009;63:630-641.